Alzheimer's 5: Use of Pharmacotherapy for Patients with Neurocognitive Disorder
This activity includes video lectures and is the fifth in a series of courses that seek to educate clinicians on standardized screening, evaluation, and disease management of Alzheimer's disease and related dementias. This fifth course focuses on the most frequently used and FDA-approved prescription medications for Alzheimer's disease and dementias, the current research regarding its use, and guidelines for prescribing and discontinuing medication. The program will incorporate cultural values and beliefs when creating and sharing the pharmacological care plan.
|Course ID #:||TJE 221137.0||Issue Date:||8/23/2022||Expiration Date:||8/23/2025|
After completing this activity, learners will be able to:
- Discuss the benefits and risks of pharmacotherapy with patients and family members/caregivers
- Review and re-evaluate side effects of medications and when it is appropriate to discontinue
- Adopt new pathways of thinking - both pharmacologic and non-pharmacologic strategies.
No individual in a position to control or influence the content of this activity has reported relevant financial relationships with commercial interests. No commercial support was provided for this activity.
The information and guidelines contained in this activity are generalized and may not apply to all practice situations. We recommend that legal advice be obtained from a qualified attorney for specific application to your practice. The information is intended for educational purposes and should be used as a reference guide only.
Michael Lobatz, MD, Co-Chair, Alzheimer's Disease Clinical Roundtable, Scripps Health
Ian Neel, MD, Geriatrician, UC San Diego
Barbara Mandel, MBA, Alzheimer's Project Facilitator, Champions for Health
Johanna Lackner, MPH, MSW, Senior Director, Continuing Professional Development, Department of Patient Safety and Risk Management, The Doctors Company
Continuing Education Credit
The Doctors Company is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical educational activities for physicians.
The Doctors Company designates this activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Doctors Company and Champions for Health. The Doctors Company is accredited by the ACCME to provide continuing medical education for physicians.
Complies with State Requirements
Please SEE the Federation of State Medical Boards overview of Continuing Medical Education requirements by State.
If you have questions about the content of this course or The Alzheimer’s Project, contact Barbara Mandel, Barbara.Mandel@ChampionsFH.org.
If you have questions, contact email@example.com or call 800. 421-2368.
Visit The Alzheimer's Project Resources associated with this program.